ISV-303
DrugBromfenac in DuraSite
NCT Number: NCT01576952
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of topical administration of ISV-303 compared with DuraSite Vehicle.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Bromfenac in DuraSite
DuraSite Vehicle
Time frame: 15 days
Anterior chamber cell grade 0 at Day 15 measured on a 0 to 4 scale where "0" is 0 cells; "1" is 1-10 cells; "2" is 11-20 cells; "3" is 21-50 cells; "4" is > 50 cells, and no rescue medications.
Sun Pharmaceutical Industries Limited
Industry
A Randomized Double-Masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects
Acronym: ISV-303
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07588074
Conjunctival Diseases, Conjunctivitis
Baton Rouge, Louisiana, United States
View Trial DetailsNCT02128113
Cataract Surgery, Corneal Diseases
Laguna Hills, California, United States
View Trial DetailsNCT04690829
Eye Diseases, Ocular Inflammation
Bethesda, Maryland, United States
View Trial DetailsNCT04374656
COVID-19, Conjunctival Diseases
Baltimore, Maryland, United States
View Trial Details